APLS · Categories · Upgrades
APLS - Analyst upgrades
Apellis Pharmaceuticals Inc. (APLS) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for APLS
- Apellis Pharmaceuticals upgraded by BofA Securities with a new price targetBofA Securities upgraded Apellis Pharmaceuticals from Neutral to Buy and set a new price target of $28.00
- Apellis Pharmaceuticals upgraded by Jefferies with a new price targetJefferies upgraded Apellis Pharmaceuticals from Hold to Buy and set a new price target of $80.00 from $68.00 previously
- Apellis Pharmaceuticals upgraded by JP Morgan with a new price targetJP Morgan upgraded Apellis Pharmaceuticals from Neutral to Overweight and set a new price target of $81.00 from $60.00 previously
- Apellis Pharmaceuticals upgraded by Wells Fargo with a new price targetWells Fargo upgraded Apellis Pharmaceuticals from Equal Weight to Overweight and set a new price target of $64.00 from $34.00 previously
- Apellis Pharmaceuticals upgraded by WedbushWedbush upgraded Apellis Pharmaceuticals from Neutral to Outperform